Divergent roles of skeletal muscle 11β-HSD1 in age-related and chronic kidney disease-associated sarcopenia
European Journal of Endocrinology · 30.04.2026 · 194 (5) · 627-640
DOI: 10.1093/ejendo/lvag075 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Endocrinology, online erschienen am 30.04.2026. Verfasst von Michael S Sagmeister und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Health Sciences, School of Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham , B152TT, UK. Hauptthemen laut MEDLINE: Sarcopenia, Renal Insufficiency, Chronic, Aging, 11-beta-Hydroxysteroid Dehydrogenase Type 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Royal Society, Royal Society Dorothy Hodgkin Fellowship.
Abstract (Originalsprache)
Background
Chronic kidney disease (CKD) is associated with increased incidence of sarcopenia and muscle weakness in aging patients. The glucocorticoid-activating enzyme11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) within skeletal muscle in these patients has been implicated in driving this process. We hypothesized that skeletal muscle 11β-HSD1 is elevated in CKD and aging, where it would represent a promising therapeutic target.
Methods
We measured 11β-HSD1 activity in quadriceps biopsies from 17 CKD patients (eGFR <30 mL/min) and 14 age-matched controls (mean age 71 ± 5 years). Muscle strength, mass, and gait speed were assessed in relation to tissue 11β-HSD1 activity. Primary human myotubes were treated with patient-derived sera to evaluate regulatory drivers. Murine models of CKD (adenine diet) and aging (21 months) in wild-type (WT) and 11β-HSD1 knockout (11βKO) animals were examined to model therapeutic targeting.
Results
Muscle 11β-HSD1 activity was not elevated with CKD, but increased with age (r = 0.559, P = .001), predicting lower grip strength (P = .008). Markers of inflammation, including C-reactive protein and IL-6, strongly predicted 11β-HSD1 activity. Pro-inflammatory mediators such as TNFα directly upregulated 11β-HSD1 activity in myotubes, whilst sera from CKD donors did not. Whilst mice with 11βKO deletion were not protected from CKD-driven muscle atrophy, 11βKO animals showed marked protection against age-related muscle loss.
Conclusions
Skeletal muscle 11β-HSD1 activity is not induced by CKD itself, but increases significantly over aging, where it is a predictor of muscle weakness. Its targeted deletion preserves muscle mass in aged mice, supporting its efficacy in preventing sarcopenia in an aging CKD population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Applied Health Sciences, School of Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham , B152TT, UK.
- Department of Metabolism and Systems Science, School of Medical Sciences, College of Medicine and Health, University of Birmingham, Birmingham B152TT, UK.
- School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham B152TT, UK.
- Department of Inflammation and Ageing, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham B152TT, UK.
- Centre for Translational Medicine and Therapeutics, William Harvey Research Institute, Queen Mary University of London, London EC1M 6BQ, United Kingdom.
- Centre for Systems Health and Integrated Metabolic Research, Department of Biosciences, Nottingham Trent University, Nottingham NG7 2RD, UK.
ORCID-Profile: Michael S Sagmeister, Helen M McGettrick, Asif J Iqbal, Lorraine Harper, Rowan S Hardy
Förderung
- Medical Research Council
- Royal Society
- Royal Society Dorothy Hodgkin Fellowship
- Birmingham Fellowship
- Academy of Medical Sciences Springboard Award
- National Institute for Health Research
- Birmingham Biomedical Research Centre
Zitieren
APA
Sagmeister, M. S., Crastin, A., Welsh, B., Firkins, L., Cassidy, B., Nicholson, T., Hopkin, S. J., Wall, N., Taylor, A. E., Kieswich, J. E., Yaqoob, M. M., Lavery, G., Chimen, M., McGettrick, H. M., Iqbal, A. J., Breen, L., Jones, S. W., Harper, L., & Hardy, R. S. (2026). Divergent roles of skeletal muscle 11β-HSD1 in age-related and chronic kidney disease-associated sarcopenia. European Journal of Endocrinology, 194(5), 627-640. https://doi.org/10.1093/ejendo/lvag075
Vancouver
Sagmeister MS, Crastin A, Welsh B, Firkins L, Cassidy B, Nicholson T, et al. Divergent roles of skeletal muscle 11β-HSD1 in age-related and chronic kidney disease-associated sarcopenia. European Journal of Endocrinology. 2026;194(5):627-640. doi:10.1093/ejendo/lvag075
BibTeX
@article{Sagmeister2026,
author = {Sagmeister, Michael S and Crastin, Ana and Welsh, Bradley and Firkins, Louise and Cassidy, Ben and Nicholson, Thomas and Hopkin, Sophie J and Wall, Nadezhda and Taylor, Angela E and Kieswich, Julius E and Yaqoob, Muhammad M and Lavery, Gareth and Chimen, Myriam and McGettrick, Helen M and Iqbal, Asif J and Breen, Leigh and Jones, Simon W and Harper, Lorraine and Hardy, Rowan S},
title = {Divergent roles of skeletal muscle 11β-HSD1 in age-related and chronic kidney disease-associated sarcopenia},
journal = {European Journal of Endocrinology},
year = {2026},
volume = {194},
number = {5},
pages = {627--640},
doi = {10.1093/ejendo/lvag075}
}
EUVIMED